• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Lymphostasis and Hemostasis in Body-Contouring Surgery Using a Polysaccharide Based Hemostat (4DryField PH)
Conclusions: This is the first prospective, monocentric, randomized study on 4DF in body-contouring surgery. The use of 4DF did not lead to a better postoperative outcome regarding hemostasis and lymphostasis. Potential benefits need further evaluation in high-volume studies.
Source: Plastic and Reconstructive Surgery – Global Open - March 1, 2019 Category: Cosmetic Surgery Tags: Original Article Source Type: research

Cohera Medical, Inc.® Enters Agreement with B. Braun Surgical, S.A. for Distribution of TissuGlu® Surgical Adhesive in Select European Countries
PITTSBURGH, Jan. 21, 2015 /PRNewswire/ -- Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that it has entered into an exclusive sales and marketing distribution agreement with B. Braun for its TissuGlu® Surgical Adhesive in Germany, Spain and Portugal.The Agreement outlines a relationship between the two companies wherein B. Braun Surgical, S.A. will exclusively market and sell TissuGlu in the territories of Germany, Spain and Portugal through its existing Closure Technologies commercial tea...
Source: Medical Hemostat - February 10, 2015 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Cohera Medical, Inc. ® Enters Agreement with B. Braun Surgical, S.A. for Distribution of TissuGlu® Surgical Adhesive in Select European Countries
PITTSBURGH ,   Jan. 21, 2015  /PRNewswire/ -- Cohera Medical, Inc. ® , a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that it has entered into an exclusive sales and marketing distribution agreement with B. Braun for its TissuGlu ®  Surgical Adhesive in   Germany ,   Spain  and   Portugal . The Agreement outlines a relationship between the two companies wherein B. Braun Surgical, S.A. will exclusively market and sell TissuGlu in the territories of   Germany ,   Spain  and   Portugal  through its existing Closur...
Source: Medical Hemostat - February 10, 2015 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Cohera Medical, Inc.® Receives PMA Approvable Letter from U.S. FDA for TissuGlu® Surgical Adhesive
PITTSBURGH, Jan. 6, 2015 /PRNewswire/ -- Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that it has received a letter from the U.S. Food and Drug Administration (FDA) that the pending Premarket Approval Application (PMA) for its TissuGlu® Surgical Adhesive is Approvable.  The receipt of the Approvable Letter means that the FDA has largely approved all parts of the PMA. The Company expects to work with the FDA to reach a final approval on the application within a few weeks."The receipt of the PMA Approvable Letter is a truly significant mileston...
Source: Medical Hemostat - January 6, 2015 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Cohera Medical, Inc. ® Receives PMA Approvable Letter from U.S. FDA for TissuGlu® Surgical Adhesive
PITTSBURGH, Jan. 6, 2015 /PRNewswire/ -- Cohera Medical, Inc. ®, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that it has received a letter from the U.S. Food and Drug Administration (FDA) that the pending Premarket Approval Application (PMA) for its TissuGlu® Surgical Adhesive is Approvable.  The receipt of the Approvable Letter means that the FDA has largely approved all parts of the PMA. The Company expects to work with the FDA to reach a final approval on the application within a few weeks. " The receipt of the PMA Approvable Letter is a truly significant mi...
Source: Medical Hemostat - January 5, 2015 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Cohera Medical, Inc.® Completes Fourth and Final Module in the Premarket Approval (PMA) Application for TissuGlu® Surgical Adhesive
PITTSBURGH, Nov. 19, 2013 -- PITTSBURGH, Nov. 19, 2013 /PRNewswire/ -- Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today it has submitted its fourth and final module for TissuGlu® Surgical Adhesive in the Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA)."We are pleased to have submitted the final module of the PMA application for TissuGlu," said Chad Coberly, JD Vice President of Clinical, Regulatory and Legal affairs of Cohera Medical. "This module culminates substantial work by the Cohe...
Source: Medical Hemostat - November 19, 2013 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs